Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial to Evaluate the Safety and Effectiveness of the Raindrop Near Vision Inlay for Pseudophakic Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03017612
Recruitment Status : Terminated (Change of inlay from no bevel to bevel design)
First Posted : January 11, 2017
Results First Posted : March 1, 2018
Last Update Posted : March 1, 2018
Sponsor:
Information provided by (Responsible Party):
ReVision Optics, Inc.

Brief Summary:
The objective of this study is to evaluate the safety and effectiveness of the Raindrop Near Vision Inlay implanted in bilateral pseudophakes with presbyopia for improvement of near and intermediate vision. The ReVision Optics corneal inlay is a 2.0-mm, 30-micron inlay made of a hydrogel material, implanted under a lasik flap. Subjects must require reading add from +1.50 D to +2.50 D. Subjects must have a preoperative manifest refraction spherical equivalent of -0.50 to +1.00 D with no more than 0.75 D of refractive cylinder. The Raindrop Near Vision Inlay will be implanted in the non-dominant eye.

Condition or disease Intervention/treatment Phase
Presbyopia Device: Raindrop Near Vision Inlay Not Applicable

Detailed Description:

Presbyopia is a natural outcome of pseudophakic subjects with monofocal or toric intraocular lenses. Treatment of pseudophakic presbyopia generally consists of reading glasses, contact lenses, or monovision LASIK, which allows the patient to see near objects. All these options suffer limitations from the patient perspective. For example, reading glasses can easily be lost or not conveniently available. Multifocal contact lenses suffer from visual symptoms and instability due to potential rotation and movement of the contact lenses on the surface of the cornea. And, successful monovision is generally limited to patients with a history of successful use of contact lenses for monovision, and even in these eyes, monovision is associated with a substantial decrease in stereo acuity and contrast sensitivity.

ReVision Optics has developed the Raindrop Near Vision Inlay for the correction of near and intermediate vision. The inlay is the same refractive index as the human cornea. The inlay is placed in the non-dominant eye, centered over the pupil after a corneal flap (LASIK) has been made. The Raindrop Near Vision Inlay is expected to provide low induction of visual symptoms and improvement of near and intermediate vision in emmetropic subjects with presbyopia. This technology may also demonstrate potential clinical utility in bilateral pseudophakic subjects.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc., Raindrop Near Vision Inlay for the Improvement of Near and Intermediate Vision in Pseudophakic Subjects
Study Start Date : July 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Single Arm Study
Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
Device: Raindrop Near Vision Inlay
A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.




Primary Outcome Measures :
  1. Percentage of Implanted Eyes With Improvement in Uncorrected Near Vision [ Time Frame: 12 months postoperatively ]
    75% of implanted eyes should achieve uncorrected near visual acuity (40cm/16in) of 20/40 or better


Secondary Outcome Measures :
  1. Preservation of Best Corrected Visual Acuity [ Time Frame: at 6 months postoperatively and all subsequent time points up to 24 months ]
    Fewer than 5% of eyes should lose two lines or more of best corrected distance and near visual acuity and less than 1% of eyes with preoperative best corrected visual acuity (BCVA) of 20/20 should have best corrected distance and near visual acuity worse than 20/40

  2. Percentage of Implanted Eyes With a Postoperative Manifest Refraction Astigmatism That Increased From Baseline by Greater Than 2.00 D [ Time Frame: At 6 months postoperatively and all subsequent time points up to 24 months ]
    Fewer than 5% of eyes should have postoperative manifest refractive astigmatism that increases from baseline by greater than 2.00 D

  3. Occurrence of Adverse Events [ Time Frame: During the length of the study, up to 24 months ]
    Any specific adverse event should occur in less than or equal to 5% of eyes.

  4. Uncorrected Intermediate Visual Acuity [ Time Frame: at 12 months postoperatively ]
    75% of eyes should achieve uncorrected intermediate visual acuity (80 cm/32 in) of 20/40 or better



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must provide informed consent, have signed the written informed consent form, and been given a copy.
  2. Subjects must be bilateral pseudophakic adults with presbyopia, needing reading add from +1.50 D to +2.50 D.
  3. Subjects must have uncorrected near visual acuity worse than 20/40 and better than 20/200 in the non-dominant eye.
  4. Subjects must have an uncorrected distance visual acuity of 20/25 or better in both eyes.
  5. Subjects must have distance and near visual acuity correctable to at least 20/20 in both eyes.
  6. Subjects must have a manifest refraction spherical equivalent (MRSE) between - 0.50 and +1.00 D with no more than 0.75 D of refractive cylinder in the non- dominant eye.
  7. Subjects must have a tear break-up time (TBUT) of ≥8 seconds.
  8. Subjects must have a central corneal thickness of between 500 and 600 microns in the non-dominant eye.
  9. Subjects must have an average corneal power of ≥ 41.00 D and ≤ 47.00 D in the non-dominant eye.
  10. Subjects must have a photopic pupil size of ≥3.0 mm, in the non-dominant eye.
  11. Subjects must have an estimated endothelial cell count of ≥ 2000 cells/mm2 in the non-dominant eye.
  12. Subjects must be willing and able to return for scheduled follow-up examinations for 24 months after surgery.
  13. Subjects must have documented monovision tolerance.
  14. Subjects must have a minimum of 3 months between cataract surgery and implantation of the Raindrop Near Vision Inlay in the non-dominant eye.
  15. Subjects must be able to demonstrate refractive stability after cataract surgery (e.g. No change in MRSE greater than ± 0.50 D within the last 2 consecutive visits at least 2 months apart) in the non-dominant eye.
  16. Subjects must have a clear or open posterior capsule in the non-dominant eye. -

Exclusion Criteria:

  • 1. Subjects with anterior chamber IOLs, or posterior chamber, accommodating, or multifocal intraocular lenses (IOLs) in either eye.

    2. Subjects with anterior segment pathology in either eye.

    3. Subjects who have worn soft or rigid contact lenses within the past 30 days in the eye to be treated.

    4. Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease (e.g., meibomian gland dysfunction), or any corneal abnormality (including endothelial dystrophy, guttata, recurrent corneal erosion, etc.) in either eye.

    5. Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in either eye.

    6. Subjects with distorted or unclear corneal mires on topography maps of the non- dominant eye.

    7. Subjects who require canthotomy to generate a corneal flap in the non-dominant eye.

    8. Subjects with macular degeneration, retinal detachment, or any other fundus pathology that would prevent an acceptable visual outcome in either eye.

    9. Subjects who have undergone previous corneal surgery including LASIK surgery in the non-dominant eye.

    10. Subjects with a history of herpes zoster or herpes simplex keratitis.

    11. Subjects who have a history of steroid-responsive rise in intraocular pressure, preoperative IOP > 21 mm Hg, glaucoma, or are a glaucoma suspect in either eye.

    12. Subjects with a history of uncontrolled diabetes, autoimmune disease connective tissue disease, or clinically significant atopic syndrome.

    13. Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing, and any immunocompromised subjects.

    14. Subjects who are using ophthalmic medication(s) other than artificial tears for treatment of any ocular pathology excluding ocular allergy.

    15. Subjects using systemic medications with significant ocular side effects.

    16. Subjects with known sensitivity to planned study concomitant medications.

    17. Subjects who are participating in any other clinical trial during the course of this clinical investigation.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03017612


Locations
Layout table for location information
United States, California
Harvard Eye Associates
Laguna Hills, California, United States, 92653
Coastal Vision
Orange, California, United States, 92868
United States, Minnesota
Chu Vision Institute
Bloomington, Minnesota, United States, 55420
United States, Texas
Key-Whitman Eye Center
Dallas, Texas, United States, 75204
Carter Eye Center
Dallas, Texas, United States, 75205
Parkhurst-NuVision
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
ReVision Optics, Inc.
Investigators
Layout table for investigator information
Study Chair: Roger Steinert, MD Interim Dean, School of Medicine; Irving H. Leopold Professor of Ophthalmology; University of Californa, Irvine, CA

Layout table for additonal information
Responsible Party: ReVision Optics, Inc.
ClinicalTrials.gov Identifier: NCT03017612     History of Changes
Other Study ID Numbers: P13-0064
First Posted: January 11, 2017    Key Record Dates
Results First Posted: March 1, 2018
Last Update Posted: March 1, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by ReVision Optics, Inc.:
Presbyopia
Additional relevant MeSH terms:
Layout table for MeSH terms
Presbyopia
Refractive Errors
Eye Diseases